Bristol buys out cancer cell therapy partner

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio in 2021. 2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. The post Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal appeared first on MedCity News.

Bristol buys out cancer cell therapy partner

Today's biotech news includes a struggling CAR-T partner 2Seventy Bio buyout, investors yet again disappointed by Novo data, and more.

BMS absorbs CAR-T partner 2seventy bio for $286m

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m

Bristol Myers Squibb to Acquire 2seventy Bio in $286 Million All-Cash Deal - Channelchek

Key Points:– BMS is acquiring 2seventy bio for $5.00 per share, an 88% premium to its last closing price.– The deal strengthens BMS’s cell and gene therapy portfolio, particularly in multiple myeloma treatment.– The acquisition comes amid increased M&A activity in biotech, signaling confidence in the sector’s long-term potential. Bristol Myers Squibb (BMY) has announced a definitive agreement to acquire 2seventy bio (TSVT) in an all-cash deal va…

BMS to acquire longtime cell therapy partner 2seventy bio for $286m - Pharmaceutical Technology

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

From Concept to Cure: The Evolution of CAR-T Cell Therapy

The authors highlight the key milestones in CAR-T cell evolution, from its invention to its clinical applications. [Molecular Therapy] AbstractGraphical Abstract